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Abstract
Background: An analysis of medical records of young females 
who were examined in our department during a five-year period 
(2005-2009) on suspicion of pulmonary embolism (PE) in relation 
to hormonal contraception (HC). 
Material and methods: The patient sample included 86 young 
females aged 15–25 (mean 21) years who underwent a ventila-
tion/perfusion scintigraphy (V/P scan). Seventeen of them were 
examined repeatedly. Altogether, 114 scintigraphic examinations 
were performed. Lung perfusion scintigraphy was performed us-
ing a planar gamma camera (Mediso MB 9200) in 4 projections 
following 100 MBq 99mTc — MAA i.v. application with 81 mKr 
ventilation scintigraphy concurrently.
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Results: 1. Among 57/86 (66%) patients on HC, 24 (42%) had 
scintigraphic signs of PE. 2. 11/57 (19%) of them had clinical 
signs of deep venous system thrombosis of the lower limbs 
that were confirmed by sonography. 3. Leiden mutation was 
found in 9/24 (37%) patients with PE. 4. Among 29/86 (34%) 
females not taking HC, PE was detected in only 3 patients (10%). 
5. 10/17 (59%) repeatedly examined females had permanent 
post-embolic residual changes of lung perfusion. 
Conclusions: In our group of patients who underwent a P/V scan, 
42% of those on HC were diagnosed with PE on scintigraphy, 
compared to 10% of those not taking HC. Among the patients 
with PE, there were 10/24 (42%) young females with persistent 
post-embolic changes. Our study indicates that the well-known 
risk of venous thromboembolism related to the use of HC needs 
to be considered as a cause of PE even among very young 
females. In our experience, prevention of these life-threatening 
conditions in patients with a family history of venous thromboem-
bolism consists of timely examination of their thrombotic profile 
and selection of appropriate contraception.  
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Introduction
Pulmonary embolism (PE) is a common, serious, but treat-
able medical condition caused by migration of a thrombus to 
the pulmonary circulation, usually from the veins of the lower ex-
tremities [1]. It can cause death or lead to chronic thromboembolic 
pulmonary hypertension at any age. In recent years, the number 
of young females treated for PE or deep-vein thrombosis in 
the legs has been increasing in the Czech Republic. Hormonal 
contraception (HC) is an effective form of contraception used by 
100 million women world-wide. While its effect on the incidence of 
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venous thromboembolism (VTE) is not large, it is an important risk 
factor of VTE in 15–45-year-old women. As the potential risk of VTE 
in younger women has not been determined, we have performed 
a retrospective analysis of PE diagnosed by a pulmonary V/P scan 
in all 15–25-year-old females examined in our department during 
a five-year period (2005–2009) in relation to hormonal contraception. 
Material and methods
The patients group consisted of 86 females aged 15–25 years. 
(mean age 21 years) who had undergone a V/P scan. Seventeen 
of them were examined repeatedly with 1–2 control perfusion after 
PE. Altogether, 114 scintigraphic examinations were performed. 
V/P scan with planar imaging was done using a planar gamma 
camera (Mediso MB 9200) in 4 projections. Perfusion studies were 
performed with the use of 99mTechnetium (gamma energy was 140 
keV and a half-life was 6 hours) after intravenous injection of 100 
MBq 99mTc — MAA (macroaggregated human albumin); followed 
with 81mKr ventilation scintigraphy simultaneously. 81mKr is a gas pro-
duced from a generator of rubidium (81Rb). This gas has the ideal 
gamma energy of 193 keV and a half-life of 13 seconds. Data acqui-
sition of both investigations included four views: anterior, posterior, 
and right and left posterior oblique (ANT, POST, RPO, LPO), using 
low-energy collimator, 400 000 counts/image, matrix 128 × 128.
Evaluation
In our study we evaluated our findings according the recom-
mended criteria PIOPED II [1, 3].
Results
The incidence of PE in relation to hormonal contraception use 
in our group of patients is presented in Table 1. 
1.  57/86 (66%) of our patients were using HC. 
2.  Among the 57 on HC, 24 (42%) had scintigraphic signs of PE. 
3.  Among 29/86 (34%) females not using HC, PE was detected 
in 3 patients (10%) only. Pathological scintigraphic findings of 
PE were evident and quite large at V/P scans in the majority 
of the positive cases (Figure 1). Their evaluation was usually 
without diagnostic problems. Changes with multiple, very small 
defects were found rarely (Figures 2 and 4). Recanalisation of 
the lungs was a common finding (Figure 3).
4.  11/57 (19%) of them had clinical signs of deep venous sys-
tem thrombosis of lower limbs that were confirmed by 
sonography. 
5.  Leiden mutation was found in 9/24 (37%) patients with PE. 
6.  10/17(59%) females who were examined repeatedly had 
permanent post-embolic residual changes of lung perfusion 
(Figure 5). 
Discussion
PE presents with recognized patterns of symptoms that may 
include unexplained breathlessness, chest pain (central or pleu-
ritic), cough, haemoptysis, syncope, palpitations, tachypnoea, 
tachycardia (heart rate > 100 bpm), cyanosis, fever, hypotension 
(systolic blood pressure < 100 mm Hg), right heart failure, pul-
monary hypertension, and leg swelling.
Table 1. Incidence of pullmonary embolism (PE) in relation to hormonal contraception use in our group of patients
HC No 
(%)
Positive signs of PE
No (%)
Negative signs of PE 
No (%)
HC use 57 (66%) 24 (42%) 33 (58%)
HC not use 29 (34%) 3 (10%) 26 (90%)
Total 86 (100%) 27 (31%) 59 (69%)
HC — hormonal contraception
Figure 1. V/P scans with of the high probability of the bilateral pullmonary embolism (PE) in a 24-year-old woman. Scans with multiple perfusion 
defects of both lungs (upper row), scans with homogenous lung ventilation. 
 Perf. — AP Perf. — RPO Perf. — LPO Perf. — PA 
 Venti. — AP Venti. — RPO Venti. — LPO Venti. — PA 
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However, these clinical features are also common in pa-
tients without PE. They may develop abruptly or insidiously over 
days and weeks. While certain symptoms and signs are more 
commonly observed in PE than in other conditions, the diagnosis of 
PE cannot be made from clinical features alone. Rather, it must 
be confirmed or refuted on the basis of a conclusive imaging test, 
 Perf. — AP Perf. — RPO Perf. — LPO Perf. — PA 
 Venti. — AP Venti. — RPO Venti. — LPO Venti. — PA 
Figure 2. V/P scans with pathological signs in a 25-year-old woman with chronic thromboembolic pulmonary hypertension (CTEPH). 
Scans with multiple, very small perfusion defects of the lungs (upper row), scans with homogenous lung ventilation (bottom row). 
Figure 3. Scan with large perfusion defects (upper row), normalization of the pathologic signs after anticoagulative therapy (bottom row) 
in a 17-year-old girl with pullmonary embolism (PE). 
 Perf. — AP Perf. — RPO Perf. — LPO Perf. — PA 
 Perf. — AP Perf. — RPO Perf. — LPO Perf. — PA 
Figure 4. Comparison of pre therapy perfusion scan (upper row), with post therapy perfusion scan (bottom row). No recanalisation after 3 weeks 
of therapy. 
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performing a V/P scan, or multidetector computed tomography 
of the pulmonary arteries (MDCT). Pulmonary angiography (PA) 
is considered to be the “gold standard”, but it is invasive, difficult to 
perform, and not readily available and is now rarely used in routine 
clinical practice. Methods based upon magnetic resonance have 
not yet been established [2, 3].
V/P scan is more readily available than MDCT but access to 
both techniques is vital for the diagnosis of PE. MDCT is often 
contraindicated for complications including an allergy or con-
trast-agent extravasation. By contrast, a V/P scan has no contrain-
dications, complications do not occur, and it carries a much lower 
radiation burden than MDCT. Therefore, V/Pscan is recommended 
as a first-line procedure in young patients, especially females, with 
suspected PE [3, 4].
The main indication for V/P scan in our study were succes-
sive PEs, commonly caused by migration of a thrombus to the 
pulmonary circulation. Usually, this is due to the embolism of 
a blood clot from the deep veins in the legs, a process termed 
venous thromboembolism (VTE). 
Multiple risk factors of VTE are congenital and acquired [5]. 
Congenital genetic causes of the hypercoagulable state: anti-
thrombin III deficiency, deficiency of the other coagulative inhibi-
tors, C and S protein deficiency, factor II deficiency (prothrombin 
deficiency), and factor V Leiden mutation. Acquired predisposition 
of VTE: extensive varicose vein, obesity, trauma, surgery, malig-
nancy, antiphospholipid syndrome, and some kinds of medica-
tion — not least HCs. A more recently recognized risk factor 
is long-distance flights, even in healthy individuals [6]. It is well 
known that the use of oestrogen-progesterone-OC gives rise to 
a risk of VTE. Therefore, lower oestrogen medication has begun 
to be applied in common practice, but a risk of VTE persists. VTE 
risk depends, in addition to the oestrogens, on the presence of 
progestin and its types as well. In the literature more papers were 
noted which were devoted to the effect of OC use on the emer-
Figure 5. Development of the postembolic residual perfusion changes in a 20-year-old woman after pullmonary embolism (PE). First examination 
immediately after PE (upper row), second examination 3 weeks (medium row) after PE, third examination 8 weeks (bottom row) after PE. 
gence of VTE risk [7, 8]; a few of them compared and assessed 
the VTE risk in third- and second-generation OCs [9, 10]. For VTE 
development, time is also very important — how long a woman 
uses OCs [11]. The risk of venous thrombosis in current users of 
combined OCs decreases with duration of use and decreasing 
oestrogen dose. For the same dose of oestrogen and the same 
length of use, OCs with desogestrel, gestodene, or drospirenone 
were associated with a significantly higher risk of venous throm-
bosis than OCs with levonorgestrel. Progestogen-only pills and 
hormone-releasing intrauterine devices were not associated with 
any increased risk of venous thrombosis [12].
The relatively small risk of VTE attributable to oral HC use 
may interact geometrically with the procoagulant mutations and 
the combination of the mutations in the prothrombin gene, and 
factor V Leiden is associated with a greater risk of thrombosis. 
The relative risk for VTE in women who have this station is ap-
proximately 35 for OC users compared with nonusers [13]. 
Leiden mutation was the most frequent finding in our group of 
patients. Two thirds of our patients used per oral HCs. But that 
is a big heterogeneous group in which women were medicated 
with different sorts of HCs (second or third generation oral 
contraceptives) and during different time periods (1–7 years). 
Overall, the young women who have undergone PE are not nu-
merous, but the prevention of this life-threatening status should 
be more consistent with a detailed personal and family history 
of VTE and timely examination of their thrombotic profile before 
OC pill prescription.
Conclusions 
The majority of our patients who underwent a V/P used HC. 
PE was confirmed by scintigraphy in 42% of them. In comparison, 
only 10% of females not using HC were positive for PE. 42% of 
patients with PE had persistent postembolic changes. 
 Anterior RPO LPO Posterior 
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The risk of venous thromboembolism related to the use of HC 
is well known. Our study indicates that VTE needs to be considered 
as a cause of PE even in very young females.  
In our experience, prevention of this life-threatening status in 
patients with family history of venous thromboembolism consists of 
timely examination of their thrombotic profile and selection of ap-
propriate contraception.
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